Fiche société
University Hospital, Lille
Traitements, essais et publications liés.
Traitements9programmes
Essais7liés
Publications8liées
SourceDBlocale
Traitements
9| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| deferiproneDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Parkinson, Sclérose latérale amyotrophique | Phase 2/3 | Neuroprotection | France | À vérifier |
| OfatumumabThis is an observational cross-sectional study of Ocrelizumab or Ofatumumab administrations for Relapsing forms of Multiple Sclerosis (RMS) in selected sites in the US, the UK and Australia. | SEP | À vérifier | Remyélinisation | France | À vérifier |
| Sodium tissue concentration will be measured in perihematomal oedemaIntracerebral haemorrhage is the type of stroke with the highest mortality rate, estimated at 40% in the acute phase. Among survivors, half will experience functional disability. Currently, there is no validated effective treatment. Reduction of perihematomal oedema is a potential therapeutic target. The development of oedema in the days following the haemorrhage worsens functional prognosis, notably through a harmful inflammatory process. In the early phase, neuronal excitotoxicity induced by the hematoma plays a major role in triggering the inflammatory cascade. This phenomenon is associated with dysfunction of neuronal Na⁺/K⁺ ATPase pumps and a disturbance of cerebral sodium homeostasis. Ultra-high field 7T MRI enables in vivo quantification of brain sodium concentrations. The investigators hypothesize that a drop-in sodium concentration within the perihematomal oedema is associated with greater oedema expansion and poorer functional outcome. To make this biomarker accessible to centers without 7 Tesla MRI, the investigators will use an artificial intelligence algorithm to generate synthetic sodium concentration maps derived from data acquired on conventional 3 Tesla MRI. | Accident vasculaire cérébral | Non applicable | Immunomodulation | À vérifier | |
| deferiproneDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Sclérose latérale amyotrophique | Non applicable | Neuroprotection | France | À vérifier |
| deferipronePeripheral blood mononuclear cells (PBMC) and platelets could be interesting ex vivo models to study brain diseases. Indeed, there is no access to neurons from patients. However, PBMC can exhibit different physiopathological mechanisms that are ubiquitous (i.e. oxidative stress, mitochondriopathy with energy metabolism, inflammation, protein folding, iron metabolism and programmed cell death ...). The platelets are pivotal in the healing system with large range of growth factors. A new therapeutic concept of conservative iron chelation with deferiprone for neuroprotection is under development. The action of deferiprone on the different mechanisms and notably the oxidative stress are to obtain from a collection of PBMC and platelets from patient having Parkinson's disease and Amyotrophic lateral sclerosis and healthy controls to study ex vivo. PBMC and platelets will be stored for future analyses. | Parkinson | Phase 2/3 | Neuroprotection | France | À vérifier |
| deferiproneDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Sclérose latérale amyotrophique | Phase 2/3 | Neuroprotection | France | À vérifier |
| OfatumumabThis is an observational cross-sectional study of Ocrelizumab or Ofatumumab administrations for Relapsing forms of Multiple Sclerosis (RMS) in selected sites in the US, the UK and Australia. | SEP | À vérifier | Remyélinisation | United States | À vérifier |
| Sodium tissue concentration will be measured in perihematomal oedemaIntracerebral haemorrhage is the type of stroke with the highest mortality rate, estimated at 40% in the acute phase. Among survivors, half will experience functional disability. Currently, there is no validated effective treatment. Reduction of perihematomal oedema is a potential therapeutic target. The development of oedema in the days following the haemorrhage worsens functional prognosis, notably through a harmful inflammatory process. In the early phase, neuronal excitotoxicity induced by the hematoma plays a major role in triggering the inflammatory cascade. This phenomenon is associated with dysfunction of neuronal Na⁺/K⁺ ATPase pumps and a disturbance of cerebral sodium homeostasis. Ultra-high field 7T MRI enables in vivo quantification of brain sodium concentrations. The investigators hypothesize that a drop-in sodium concentration within the perihematomal oedema is associated with greater oedema expansion and poorer functional outcome. To make this biomarker accessible to centers without 7 Tesla MRI, the investigators will use an artificial intelligence algorithm to generate synthetic sodium concentration maps derived from data acquired on conventional 3 Tesla MRI. | Accident vasculaire cérébral | Non applicable | Immunomodulation | À vérifier | |
| OfatumumabThis is an observational cross-sectional study of Ocrelizumab or Ofatumumab administrations for Relapsing forms of Multiple Sclerosis (RMS) in selected sites in the US, the UK and Australia. | SEP | À vérifier | Remyélinisation | France | À vérifier |
Essais cliniques
7| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Ofatumumab | SEP | À vérifier | NCT07625800 | SOLI — Switch to Ofatumumab and Level of Immunoglobulins | RECRUITING |
| Sodium tissue concentration will be measured in perihematomal oedema | Accident vasculaire cérébral | Non applicable | NCT07789990 | TIPITCH-7T — Characterization of Peri-Hemorrhagic Cerebral Edema Using Synthetic Sodium Imaging With 7-Tesla and 3-Tesla MRI | NOT_YET_RECRUITING |
| Ofatumumab | SEP | À vérifier | NCT05171972 | Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment | COMPLETED |
| deferiprone | Sclérose latérale amyotrophique | Phase 2/3 | NCT03293069 | FAIR-ALS II — Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis | COMPLETED |
| deferiprone | Parkinson | Phase 2/3 | NCT00943748 | FAIR-PARK-I — Efficacy and Safety of the Iron Chelator Deferiprone in Parkinson's Disease | COMPLETED |
| deferiprone | Sclérose latérale amyotrophique | Non applicable | NCT02880033 | LymphoEnergy — Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes | COMPLETED |
| MRI | Myopathies | À vérifier | NCT04656210 | Myotonic Dystrophy - Vascular and Cognition | ACTIVE_NOT_RECRUITING |
Publications
8| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| deferiprone | Therapeutic Silencing of Tmprss6 Reduces Iron-Induced Inflammation and Prolongs Survival in MDS Mice. | American journal of hematology | ||
| deferiprone | Trace Elements Dyshomeostasis and Toxic Metals Neurotoxicity in Neurodegenerative Diseases. | Biological trace element research | ||
| Ofatumumab | Immunoglobulin dynamics and infection risk with ofatumumab versus ocrelizumab in multiple sclerosis. | Multiple sclerosis and related disorders | ||
| deferiprone | Precision Medicine in Transfusion-Dependent and Non-Transfusion-Dependent β-Thalassemia: Toward Personalized Diagnosis and Therapy. | Hemoglobin | ||
| deferiprone | Amelioration of Cisplatin Nephrotoxicity by Fe-Pt Coordination Exchange-Triggered Ferroptosis Suppression. | Advanced healthcare materials | ||
| Ofatumumab | Eculizumab treatment in the salvage therapy of MOGAD: a case report. | Frontiers in immunology | ||
| Ofatumumab | Lymphoplasmapheresis for Refractory Anti-N-Methyl-D-Aspartate Receptor Encephalitis: A Case Report. | Journal of clinical apheresis | ||
| Ofatumumab | Possible Contribution of Multiple Sclerosis Pathology to Treatment-Resistant Schizophrenia: A Case Study. | Neuropsychopharmacology reports |